Perspective from Steven E. Nissen, MD, MACC
October 12, 2017
1 min read
Save

Merck halts development of anacetrapib

Perspective from Steven E. Nissen, MD, MACC
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Merck has announced that applications will not be submitted for regulatory approval of anacetrapib, a cholesteryl ester transfer protein inhibitor for the treatment of patients with CVD.

Numerous studies have shown that anacetrapib not only raises HDL and lowers LDL, but also lowers the incidence of major coronary events when added to statin therapy.

As Cardiology Today has previously reported, results of the REVEAL trial, presented at the European Society of Cardiology Congress in August, showed anacetrapib was the first CETP inhibitor to demonstrate a reduction in CV events. Other trials of CETP inhibitors, including ILLUMINATE, dal-OUTCOMES and ACCELERATE, were stopped for futility or harm.

“We are grateful to the researchers and patients who participated in the anacetrapib clinical development program, and in particular the REVEAL outcomes study,” Roger M. Perlmutter, MD, PhD, president of Merck Research Laboratories, said in a press release. “Unfortunately, after comprehensive evaluation, we have concluded that the clinical profile for anacetrapib does not support regulatory filings.”

Disclosure: Perlmutter is an employee of Merck.